Aberrant Expression of Gastric Carcinoma High Expressed Transcript 1 is a Diagnostic and Prognostic Biomarker in Human Cancer

Abstract

BackgroundGastric carcinoma high expressed transcript 1 (GHET1), a long noncoding RNA (LncRNA), has been reported to be involved in tumor genesis and cancer progression. High GHET1 expression is correlated with a poor prognosis in cancer. In this meta-analysis, we investigated the association between GHET1 and lymph node metastasis, differentiation, vascular invasion and so on in human cancer. MethodsWe performed systematic search in PubMed, EMBASE, Wiley Online Library, Wiley Online Library, and Medline from January 1, 1996 to September 25, 2017. A total of 8 studies were selected for further research. ResultsThe result showed that GHET1 expression was significantly associated with OS (hazard ratio [HR] = 2.23; 95% CI, 1.86–2.67; P < 0.0001), including digestive system tumor (HR = 2.17; 95% CI, 1.63–2.89; P < 0.0001). Moreover, high GHET1 expression was related to tumor size (odds ratio [OR] = 2.15, 95% CI: 1.57–2.94; P < 0.00001), TNM stage (Ⅲ+Ⅳ vs.Ⅰ+Ⅱ; OR = 4.02, 95% CI:3.06–5.28; P < 0.00001), lymph node metastasis (Yes vs. No; OR = 3.55, 95% CI:2.54–4.95; P < 0.00001), differentiation (poor vs. well or moderate; OR = 1.72, 95% CI:1.22–2.42; P = 0.002), vascular invasion (Yes vs. No; OR = 3.03, 95% CI:1.80–5.12; P = 0.00001). Also, we found that high expression of GHET1 has a significant relationship with analysis method and sample size. It almost higher in different human cancers. ConclusionsGHET1 may serve as a potential clinical biomarker and poor survival and high-risk recurrence in cancers.